Processa Pharmaceuticals (PCSA) Competitors $0.24 -0.01 (-3.24%) As of 11:45 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock PCSA vs. ENSC, ADIL, ATNF, KTTA, SONN, DRMA, AEON, CMND, ALZN, and LIXTShould you be buying Processa Pharmaceuticals stock or one of its competitors? The main competitors of Processa Pharmaceuticals include Ensysce Biosciences (ENSC), Adial Pharmaceuticals (ADIL), 180 Life Sciences (ATNF), Pasithea Therapeutics (KTTA), Sonnet BioTherapeutics (SONN), Dermata Therapeutics (DRMA), AEON Biopharma (AEON), Clearmind Medicine (CMND), Alzamend Neuro (ALZN), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry. Processa Pharmaceuticals vs. Ensysce Biosciences Adial Pharmaceuticals 180 Life Sciences Pasithea Therapeutics Sonnet BioTherapeutics Dermata Therapeutics AEON Biopharma Clearmind Medicine Alzamend Neuro Lixte Biotechnology Ensysce Biosciences (NASDAQ:ENSC) and Processa Pharmaceuticals (NASDAQ:PCSA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation. Do analysts recommend ENSC or PCSA? Processa Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 2,299.04%. Given Processa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Processa Pharmaceuticals is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Processa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, ENSC or PCSA? Ensysce Biosciences has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Processa Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Which has preferable valuation & earnings, ENSC or PCSA? Ensysce Biosciences has higher revenue and earnings than Processa Pharmaceuticals. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$2.23M2.19-$10.61M-$13.39-0.22Processa PharmaceuticalsN/AN/A-$11.12M-$3.89-0.06 Is ENSC or PCSA more profitable? Processa Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. Processa Pharmaceuticals' return on equity of -195.21% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-179.26% -292.81% -158.83% Processa Pharmaceuticals N/A -195.21%-163.06% Does the MarketBeat Community believe in ENSC or PCSA? Processa Pharmaceuticals received 12 more outperform votes than Ensysce Biosciences when rated by MarketBeat users. CompanyUnderperformOutperformEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% Processa PharmaceuticalsOutperform Votes1560.00% Underperform Votes1040.00% Does the media prefer ENSC or PCSA? In the previous week, Ensysce Biosciences and Ensysce Biosciences both had 3 articles in the media. Processa Pharmaceuticals' average media sentiment score of 0.44 beat Ensysce Biosciences' score of 0.30 indicating that Processa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ensysce Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Processa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in ENSC or PCSA? 5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 91.9% of Processa Pharmaceuticals shares are owned by institutional investors. 7.9% of Ensysce Biosciences shares are owned by insiders. Comparatively, 13.0% of Processa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryProcessa Pharmaceuticals beats Ensysce Biosciences on 11 of the 15 factors compared between the two stocks. Get Processa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PCSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCSA vs. The Competition Export to ExcelMetricProcessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.077.3222.5118.54Price / SalesN/A241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book0.066.486.734.25Net Income-$11.12M$143.41M$3.22B$248.18M7 Day Performance5.44%2.58%1.38%1.03%1 Month Performance-16.63%5.00%2.79%2.70%1 Year Performance-88.93%-3.72%15.41%4.05% Processa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCSAProcessa Pharmaceuticals2.9619 of 5 stars$0.24-3.2%$6.00+2,379.3%-88.7%$1.28MN/A-0.0720Upcoming EarningsNews CoverageGap DownENSCEnsysce Biosciences0.1806 of 5 stars$2.93-10.9%N/A-67.4%$4.82M$2.23M-0.1110Upcoming EarningsGap UpADILAdial Pharmaceuticals3.2274 of 5 stars$0.71+4.2%$8.00+1,020.4%-55.7%$4.70MN/A-0.2220News CoveragePositive NewsGap UpATNF180 Life SciencesN/A$0.89+0.6%N/A-33.2%$4.59MN/A0.007News CoverageKTTAPasithea Therapeutics0.5244 of 5 stars$1.69-2.3%N/A-78.0%$4.57MN/A-0.133SONNSonnet BioTherapeutics1.3784 of 5 stars$1.49+8.8%$20.00+1,242.3%-24.7%$4.57M$1M0.0010Short Interest ↑Gap UpDRMADermata Therapeutics2.9281 of 5 stars$0.75+1.8%$6.00+697.9%-83.5%$4.54MN/A-0.058Upcoming EarningsPositive NewsGap DownAEONAEON Biopharma1.7102 of 5 stars$0.42-2.4%$360.00+85,614.3%-99.8%$4.42MN/A2.335Gap UpCMNDClearmind Medicine1.0831 of 5 stars$1.03+1.0%N/A-13.6%$4.39MN/A-0.55N/AShort Interest ↓Gap UpALZNAlzamend Neuro3.5029 of 5 stars$0.66-2.6%$20.00+2,921.1%-90.7%$4.38MN/A0.004Short Interest ↓Positive NewsGap UpLIXTLixte Biotechnology1.0925 of 5 stars$1.39+8.2%N/A-56.3%$4.36MN/A-0.804Upcoming EarningsPositive NewsGap Up Related Companies and Tools Related Companies Ensysce Biosciences Alternatives Adial Pharmaceuticals Alternatives 180 Life Sciences Alternatives Pasithea Therapeutics Alternatives Sonnet BioTherapeutics Alternatives Dermata Therapeutics Alternatives AEON Biopharma Alternatives Clearmind Medicine Alternatives Alzamend Neuro Alternatives Lixte Biotechnology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCSA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Processa Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Processa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PCSA Stock Free PCSA Stock Alerts